Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 30000 | 144 | 39.7 | 92% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 1629 | 6478 | UNFOLDED PROTEIN RESPONSE//ENDOPLASMIC RETICULUM STRESS//ER STRESS |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | NELFINAVIR | Author keyword | 3 | 10% | 17% | 25 |
| 2 | SAQUINAVIR NO | Author keyword | 2 | 67% | 1% | 2 |
| 3 | ANTIRETROVIRALL THERAPY | Author keyword | 1 | 50% | 1% | 1 |
| 4 | CYP 51 | Author keyword | 1 | 50% | 1% | 1 |
| 5 | INFECT DIS HEMATOL | Address | 1 | 50% | 1% | 1 |
| 6 | MIT HARVARDRAGON MGH | Address | 1 | 50% | 1% | 1 |
| 7 | RITONAVIR LOPINAVIR | Author keyword | 1 | 50% | 1% | 1 |
| 8 | SAFETY INFORMAT DRUG | Address | 1 | 50% | 1% | 1 |
| 9 | UNIT INFECT DIS 5 | Address | 1 | 50% | 1% | 1 |
| 10 | VIRUS ENDOCYTOSIS | Author keyword | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | NELFINAVIR | 3 | 10% | 17% | 25 | Search NELFINAVIR | Search NELFINAVIR |
| 2 | SAQUINAVIR NO | 2 | 67% | 1% | 2 | Search SAQUINAVIR+NO | Search SAQUINAVIR+NO |
| 3 | ANTIRETROVIRALL THERAPY | 1 | 50% | 1% | 1 | Search ANTIRETROVIRALL+THERAPY | Search ANTIRETROVIRALL+THERAPY |
| 4 | CYP 51 | 1 | 50% | 1% | 1 | Search CYP+51 | Search CYP+51 |
| 5 | RITONAVIR LOPINAVIR | 1 | 50% | 1% | 1 | Search RITONAVIR+LOPINAVIR | Search RITONAVIR+LOPINAVIR |
| 6 | VIRUS ENDOCYTOSIS | 1 | 50% | 1% | 1 | Search VIRUS+ENDOCYTOSIS | Search VIRUS+ENDOCYTOSIS |
| 7 | CELL CYCLE SPECIFIC DRUGS | 0 | 33% | 1% | 1 | Search CELL+CYCLE+SPECIFIC+DRUGS | Search CELL+CYCLE+SPECIFIC+DRUGS |
| 8 | NON SMALL CELL LUNG CARCINOMA CELLS | 0 | 33% | 1% | 1 | Search NON+SMALL+CELL+LUNG+CARCINOMA+CELLS | Search NON+SMALL+CELL+LUNG+CARCINOMA+CELLS |
| 9 | S6 PROTEIN | 0 | 33% | 1% | 1 | Search S6+PROTEIN | Search S6+PROTEIN |
| 10 | DIMETHYL CELECOXIB | 0 | 25% | 1% | 1 | Search DIMETHYL+CELECOXIB | Search DIMETHYL+CELECOXIB |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | DIMETHYL CELECOXIB DMC | 2 | 67% | 1% | 2 |
| 2 | PROTEASE INHIBITOR NELFINAVIR | 2 | 25% | 5% | 7 |
| 3 | GIT 27NO | 1 | 50% | 1% | 1 |
| 4 | METHIONINE DEPENDENCE | 1 | 50% | 1% | 1 |
| 5 | TRIB3 | 1 | 50% | 1% | 1 |
| 6 | NON COXIB ANALOG | 0 | 14% | 2% | 3 |
| 7 | LIPID SYNTHETIC GENES | 0 | 33% | 1% | 1 |
| 8 | SITE 2 PROTEASE | 0 | 18% | 1% | 2 |
| 9 | 2 5 DIMETHYL CELECOXIB | 0 | 25% | 1% | 1 |
| 10 | ANTIFUNGAL DRUG ITRACONAZOLE | 0 | 20% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs | 2014 | 9 | 60 | 35% |
| Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention | 2013 | 11 | 68 | 60% |
| Anti-HIV drugs for cancer therapeutics: back to the future? | 2009 | 58 | 69 | 28% |
| ANALYSIS OF NELFINAVIR-INDUCED ENDOPLASMIC RETICULUM STRESS | 2011 | 8 | 9 | 33% |
| Bortezomib Targets the Caspase-Like Proteasome Activity in Cervical Cancer Cells, Triggering Apoptosis That Can be Enhanced by Nelfinavir | 2011 | 17 | 29 | 10% |
| Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response | 2011 | 5 | 115 | 8% |
| A Glimpse of the Future Where Will New Combinations of Diagnostics and Therapies Take Us? | 2011 | 2 | 47 | 9% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | INFECT DIS HEMATOL | 1 | 50% | 0.7% | 1 |
| 2 | MIT HARVARDRAGON MGH | 1 | 50% | 0.7% | 1 |
| 3 | SAFETY INFORMAT DRUG | 1 | 50% | 0.7% | 1 |
| 4 | UNIT INFECT DIS 5 | 1 | 50% | 0.7% | 1 |
| 5 | BIOMED TECHNOL ASSOCIATED MED SCI | 0 | 33% | 0.7% | 1 |
| 6 | FE EN MED | 0 | 33% | 0.7% | 1 |
| 7 | INSERM U98X | 0 | 33% | 0.7% | 1 |
| 8 | LEXINGTON VA MED | 0 | 17% | 1.4% | 2 |
| 9 | JOHNS HOPKINS CLIN COMPOUND SCREENING INITIAT | 0 | 25% | 0.7% | 1 |
| 10 | MAASTRO CLINGROW ONCOL DEV BIOL | 0 | 25% | 0.7% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000215277 | BIOMARKERS BRANCH//CLONOGEN//COLORADO PARTY |
| 2 | 0.0000114367 | BORTEZOMIB//PROTEASOME INHIBITOR//PROTEASOME INHIBITORS |
| 3 | 0.0000105687 | ATAZANAVIR//RITONAVIR//LOPINAVIR |
| 4 | 0.0000103148 | EMI U 9922//UNITE PHYSIOPATHOL INFECT LENTIVIRALES//DIPARTIMENTO IGIENE MED PREVENT SANITA PUBBL |
| 5 | 0.0000099985 | HUMAN MALIGNANT GLIOMAS//MOL EXPT RADIOL//RADGENOM GRP |
| 6 | 0.0000085231 | SESTRIN 2//TP53INP1//SESTRIN |
| 7 | 0.0000080992 | LIPODYSTROPHY//LIPOATROPHY//PROGRAM NUTR METAB |
| 8 | 0.0000076738 | KAPOSIS SARCOMA//HUMAN HERPESVIRUS 8//KAPOSI SARCOMA |
| 9 | 0.0000070473 | AIDS RELATED LYMPHOMA//NON AIDS DEFINING CANCER//NON AIDS DEFINING CANCERS |
| 10 | 0.0000066378 | GRP78//BIOCHEM PROTE GRP//GLUCOSE REGULATED PROTEIN 78 |